Author's response to reviews

Title: Phase II Assessment of Talabostat and Cisplatin in Second-Line Stage IV Melanoma

Authors:

Robert M. Eager (eager.rm@gmail.com)
C. Casey Cunningham (ccunningham@terapio.com)
Neil Senzer (NSenzer@marycrowley.org)
Joe Stephenson Jr (Joe.Stephenson@USOncology.com)
Stephen P. Anthony (stephen.anthony@usoncology.com)
Steven J. O Day (soday@theangelesclinic.org)
Gary Frenette (gfrenette@carolinas.org)
Anna C. Pavlick (anna.pavlick@nyumc.org)
Barry Jones (bjones@ziopharm.com)
Margaret Uprichard (muprichard@epixpharma.com)
John Nemunaitis (JNemunaitis@marycrowley.org)

Version: 4 Date: 29 July 2009

Author's response to reviews: see over
July 28, 2009

BioMed Central Editorial Production Team
BMC Cancer

RE: Manuscript 1428665872245752 - SUBMISSION WITH FINAL CHANGES

As per the email sent on July 21, 2009 (Subject: “Formatting Changes for MS: 1428665872245752”), the manuscript has been edited to incorporate all of the formatting changes you requested. These include:

Title - ensuring that the title is identical in the manuscript and the submission system

Affiliations - Each affiliation is written in full, in the following format: department, institute, city, state, and country. Please Note: Where there is NO department, one is not listed.

Conclusions - A Conclusions section heading is inserted after the Discussion.

Details for Reference 12 are provided in full.

Table size – Tables are all re-oriented into Portrait size.

'Date: 7/9/2009' – Is removed from the title page.

Email addresses for all authors are included on the title page, as per your format.

Table titles and legends - The table title are now only one sentence long. All other text is placed as a legend (or key), appearing below the table. Also, these no longer appear within the table borders, but outside the borders at the bottom.

We have made all final corrections and revisions, and the file uploaded today into the editorial system represents the FINAL modified manuscript.

Thank you,

John Nemunaitis, M.D.
Executive Medical Director